CDEK
← All drugs Report issue

streptococcus salivarius

Cell therapyexperimental

Streptococcus salivarius is a species of spherical, gram-positive, facultative anaerobic lactic acid bacteria that is both catalase and oxidase negative. S. salivarius colonizes the oral cavity and upper respiratory tract of humans just a few hours after birth, making further exposure to the bacteria harmless in most circumstances. The bacterium is considered an opportunistic pathogen, rarely finding its way into the bloodstream, where it has been implicated in cases of sepsis in people with neutropenia,. — Wikipedia

Clinical trial activity

55 trials · 67 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
13
Phase 3
9
Phase 4
6

Earliest trial started Dec 1, 2003 (NCT00175292)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • streptococcus salivarius
  • streptococcus salivarius blis k12
  • vsl #3
  • vsl#3

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07235826N/ASep 1, 2025Liaquat University of Medical & Health Sciences, University of Urbino "Carlo Bo"
NCT06380270N/ANov 1, 2024Liaquat University of Medical & Health Sciences
NCT06370208N/ANov 1, 2024Liaquat University of Medical & Health Sciences
NCT06015958N/AOct 1, 2023BLIS Technologies Limited
NCT05624177N/ADec 31, 2022BLIS Technologies Limited
NCT05375383N/AJun 15, 2022BLIS Technologies Limited
NCT05375396N/AJun 1, 2022BLIS Technologies Limited
NCT05374070N/AMay 23, 2022BLIS Technologies Limited
NCT05367518N/AMay 15, 2022BLIS Technologies Limited
NCT05840926N/AJan 5, 2022Liaquat University of Medical & Health Sciences
NCT05918224Phase 2Jan 1, 2022Sichuan University
NCT04891523N/ASep 30, 2021University of Geneva
NCT05043376N/ASep 10, 2021King Edward Medical University
NCT05039320N/ASep 2, 2021I. Mechnikov Research Institute of Vaccines and Sera, I.M. Sechenov First Moscow State Medical University
NCT04492631N/AJul 28, 2020Dose Biosystems Inc., TKL Research
NCT04473404N/AJul 20, 2020Dose Biosystems Inc., Salus Research
NCT04297878N/AMar 5, 2020Moorgreen Hospital, Southampton
NCT03586622N/ASep 1, 2018Calpro AS, Colitis-Crohn Foreningen, Ferring, Genetic Analysis, North Zealands University Hospital, Statens Serum Institut, University of Copenhagen
NCT03682094Early Phase 1 (Phase 1)Aug 13, 2018University of Wisconsin
NCT03327051Phase 4Nov 30, 2017Stanford University
Showing 20 of 55 trials
Page 1 / 3

Organizations

Research & Development (67)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
VSL PharmaceuticalsFor profit7342004
BLIS Technologies LimitedFor profit6612022
Liaquat University of Medical & Health SciencesAcademic/Hospital4412022
Hebrew UniversityAcademic/Hospital3322004
All India Institute of Medical SciencesAcademic/Hospital2112007
CD Pharma India Pvt. Ltd.For profit2212009
Dose Biosystems Inc.For profit2212020
FerringFor profit2022010
University of LondonAcademic/Hospital2222007
University of WisconsinAcademic/Hospital2222008
Asian Institute of GastroenterologyAcademic/Hospital1112012
Calpro ASFor profit1012018
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012003
Chinese University of Hong KongAcademic/Hospital1112010
Colitis-Crohn ForeningenAcademic/Hospital1012018
Dutch Cancer SocietyAcademic/Hospital1012006
Emory UniversityAcademic/Hospital1112017
Genetic AnalysisFor profit1012018
Government Medical College, IndiaAcademic/Hospital1012016
Government Medical College, Kozhikide, Kerala, IndiaAcademic/Hospital1012016
67 organizations
Page 1 / 4